ClinicalTrials.gg
RecruitingNCT06818500Updated Apr 24, 2026

Effects of Body Composition on Vascular Health in Females With a Healthy Body Weight

An interventional study of high-fat meal and Stress in Normal-weight Obesity, BMI and Stress, sponsored by Ball State University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Ball State University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2024, registered Feb 2025).
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Most of the time, body weight is evaluated by looking at the ratio of your weight to your height. This measurement is called body mass index or BMI. However, BMI does not account for what your body is actually made up of (e.g., body fat versus muscle), which may be more important for determining cardiovascular disease risk. The investigators aim to understand vascular health in females with a "healthy" BMI with differing amounts of body fat and muscle mass. We will have participants come to the lab for two different study visits. At one visit, participants will eat a meal high in fat, and at the other visit, participants will undergo a stress task.

Read the detailed description

The investigators will recruit females with a BMI in the normal (18.5-24.9 kg/m2) from the Ball State University campus and surrounding communities. Each participant will complete a meal trial and a stress trial in a randomized crossover design. At the meal trial, an intravenous catheter will be inserted and baseline blood sample collected. Then vascular measurements (i.e., flow-mediated dilation, pulse wave analysis, pulse wave velocity) will be performed. Each time vascular measurements are performed, the participants will lie in a quiet area to acclimate prior to beginning. Next, participants will consume a high-fat, Western style meal consisting of two Jimmy Deans Breakfast Bowls (sausage; 68 g fat; 880 kcal). Following completion of the meal, blood samples will also be collected 1, 2, 3, and 4 hours after the meal. Vascular measurements will be repeated 2 and 4 hours after the meal. Blood will be collected and stored as serum in order to measure triglycerides, HDL-C, and intestinal permeability (e.g., lipopolysaccharide binding protein) using commercially available ELISAs.

At the stress trial, an intravenous catheter will be inserted and baseline blood sample collected. Then vascular measurements (i.e., flow-mediated dilation, pulse wave analysis, pulse wave velocity) will be performed. Each time vascular measurements are performed, the participants will lie in a quiet area to acclimate prior to beginning. Next, participants will undergo the stress task. Then, blood samples will be collected at 10, 60, and 90 minutes after the stress task. Blood will be collected and stored as serum in order to measure epinephrine and inflammatory markers. Vascular measurements will also be repeated 10 and 90 minutes after the stress task.

02

Conditions studied

  • Normal-weight Obesity
  • BMI
  • Stress

Browse trials for

Keywords

  • BMI
  • Stress
  • Healthy BMI
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 30 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Ball State University is the lead sponsor of 13 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You are 18-50 years old
  • Your biological sex is female
  • is in "normal" category (18.5-24.9 kg/m2) - this BMI requirement is due to our research aims
  • You are not pregnant or expecting to become pregnant
  • You are not
  • You have not been diagnosed with a cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes)
  • You have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
  • You do not regularly take anti-inflammatory drugs (more than 2x week) or are able to temporarily suspend use of anti-inflammatory drugs.
  • You do not use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin) tobacco products, or any illicit drugs
  • You do not have a pacemaker.
  • You do not have dietary restrictions prohibiting you from eating the provided meal (e.g., vegan/vegetarian diets, gluten-free diet, relevant food allergies).
  • You are able to stay in the supine position in the dark for at least 10 minutes

Exclusion criteria

Exclusion Criteria:

  • You are not 18-50 years old
  • Your biological sex is not female
  • Your is not in the "normal" category (18.5-24.9 kg/m2) - this BMI requirement is due to our research aims
  • You are pregnant or expecting to become pregnant (females only)
  • You are
  • You have been diagnosed with a cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes)
  • You have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
  • You regularly take anti-inflammatory drugs (more than 2x week) or are unable to temporarily suspend use of anti-inflammatory drugs.
  • You use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin) tobacco products, or any illicit drugs
  • You have a pacemaker.
  • You do have dietary restrictions prohibiting you from eating the provided meal (e.g., vegan/vegetarian diets, gluten-free diet, relevant food allergies).
  • You are unable to stay in the supine position in the dark for at least 10 minutes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High-fat meal trial

    During the "High-fat meal trial", participants will report fasted and consume two Jimmy Dean's breakfast bowls.

    Other: high-fat meal

  • Experimental
    Stress trial

    During the "Stress trial", participants will report fasted and undergo a stress task where they may experience mental stress.

Interventions

  • Otherhigh-fat meal

    Participants will report fasted and consume two Jimmy Dean breakfast bowls (sausage).

  • OtherStress

    Participants will report fasted and undergo a mental stress task.

06

What researchers measure

Primary outcomes

  1. Flow-mediated dilation

    The investigators will measure FMD at baseline, 2-hours, and 4-hours after meal trial. The investigators will measure FMD at baseline, post-stress task, and 90-minutes after the stress task.

    Time frame: Through study completion, up to 1 year.

  2. Pulse wave analysis

    The investigators will measure PWA (i.e., augmentation index, augmentation index normalized to a heart rate of 75bpm, aortic/peripheral blood pressure) at baseline, 2-hours, and 4-hours after meal trial using Sphygmacor Xcel System. The investigators will measure PWA at baseline, post-stress task, and 90-minutes after the stress task.

    Time frame: Through study completion, up to 1 year.

  3. Pulse wave velocity

    The investigators will measure PWV at baseline, 2-hours, and 4-hours after meal trial using the Sphygmacor Xcel System. The investigators will measure PWV at baseline, post-stress task, and 90-minutes after the stress task.

    Time frame: Through study completion, up to 1 year.

Secondary outcomes

  1. Serum high-density lipoprotein cholesterol (HDL-C)

    The investigators will measure HDL-C at baseline and 1, 2, 3, and 4 hours after the meal. Serum will be banked from each visit and this measurement will take place upon study completion.

    Time frame: Through study completion, up to 1 year.

  2. Serum triglycerides

    The investigators will measure triglycerides at baseline and 1, 2, 3, and 4 hours after the meal. Serum will be banked from each visit and this measurement will take place upon study completion.

    Time frame: Through study completion, up to 1 year.

  3. Serum soluble CD14 (sCD14)

    The investigators will measure serum sCD14 at baseline and 1-, 2-, 3-, and 4-hours after the meal. Serum will be banked from each visit and this measurement will take place upon study completion.

    Time frame: Through study completion, up to 1 year.

  4. Serum lipopolysaccharide binding protein (LBP)

    The investigators will measure serum LBP at baseline and 1-, 2-, 3-, and 4-hours after the meal. Serum will be banked from each visit and this measurement will take place upon study completion.

    Time frame: Through study completion, up to 1 year.

  5. Serum epinephrine

    The investigators will measure serum epinephrine at baseline and 10-, 60- and 90-minutes after the stress task. Serum will be banked from each visit and this measurement will take place upon study completion.

    Time frame: Through study completion, up to 1 year.

  6. Serum interleukin-6 (IL-6)

    The investigators will measure serum IL-6 at baseline and 1-, 2-, 3-, and 4-hours after the meal and 10, 60, and 90 minutes after the stress task. Serum will be banked from each visit and this measurement will take place upon study completion.

    Time frame: Through study completion, up to 1 year.

  7. Heart rate variability (HRV)

    The investigator will analyze HRV pre-, during, and post-stress task during the stress trial (Task Force Monitor).

    Time frame: Through study completion, up to 1 year.

  8. Beat-to-beat systolic and diastolic blood pressure (SBP/DBP)

    The investigator will analyze SBP/DBP pre, during, and post-stress task during the stress trial (Task Force Monitor).

    Time frame: Through study completion, up to 1 year.

Other outcomes

  1. Body composition

    The investigators will measure body composition using dual energy x ray absorptiometry (DXA).

    Time frame: Through study completion, up to 1 year.

  2. Systolic and diastolic blood pressure

    The investigators will measure blood pressure using an automated cuff (Omron).

    Time frame: Through study completion, up to 1 year.

07

Study locations

1 of 1 sites recruiting
  • Ball State University- Nutrition Assessment Lab
    Muncie, Indiana 47303, United States
    Recruiting
    • Bryant H Keirns, PhD · Contactbryant.keirns@bsu.edu · 7652858356
    • Bryant H Keirns, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for May 2027, 32 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 32 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 10, 2025
StartActual
Sep 1, 2024
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06818500
Lead sponsor
Ball State University
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Sep 1, 2024
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Apr 24, 2026

Study contacts

Bryant H Keirns, PhD
Contact
bryant.keirns@bsu.edu
7652858356

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion